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IMo13-31 Re-evaluating current antibiotic therapy
W. A. Craig
University of Wisconsin, Madison, WI, United States
Pharmacokinetic/pharmacodynamic (PK/PD) parameters derived from
animal and clinical infection models have been shown to be excellent
predictors ofbacteriologic efficacy. For example, in otitis media and sinusitis,
a high rate ofbacteriologic cure is obtained when serum concentrations of{3-
lactams and several macrolides exceed the MIC ofthe infecting pathogen for
at least 40% ofthe dosing interval. Likewise, the 24-hour AUC/MIC ratio is
a good predictor of bacteriologic and clinical efficacy for azithromycin in
otitis media and f1uoroquinolones in bacterial pneumonia.
The value of PK/PD relationships has been recognized by the National
Committee for Clinical Laboratory Standards (NCCLS) as another impor-
t:mt factor to consider when establishing susceptibility breakpoint'. Recent
breakpoints with oral {3-lactams and new f1uoroquiolones for Streptococcus
pneumoniae reflect the impact of PK/PD relationships.
Many of the same PK/PD parameters appear to be important in reducing
the emergence ofresistant organisms, Peak/MIC and AUC/MIC parameters
have been important for f1uoroquinolones. However, different f1uoroqui-
nolones may have different mutation prevention concentrations. Prolonged
durations above the MIC appear to be important for {3-laetams and
macrolides to reduce the potential for resistance development and eliminate
resistant clones of S. pneumoniae from the nasopharynx.
In an era of increasing resistance, we should select agents and doses that
provide drug concentrations that exceed the magnitude of the PK/PD
parameter required for efficacy and prevention of resistance.
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ITu19-11 MYSnC (Meropenem Yearly Susceptibility Test
Information Collection): Trends in resistance
R. N.]ones
University of Iowa College ofMedicine/CAST Laboratories, Iowa, United
States
Objectives: To describe the MYSTIC antimicrobial surveillance system and
its results during three years of operation.
Methods: Since 1997, the MYSTIC programme has assessed the activity of
meropenem and other broad spectrum antimicrobial agents on significant
bacterial strains. Bacteria ~cre collected in ho~pital" or ,;,pecific service units
which were using meropenem. Meropenem was compared with imipenem,
ceftazidime, cefepime, piperacillin/tazobactam, ciprofloxacin, gentamicin or
tobramycin using reference quality methods (NCCLS agar dilution or broth
microdilution). Procedures were also performed to detect extended spec-
trum beta-Iactamases and other inactivating enzymes.
Results: Initial baseline studies were reported from 47 centres in Europe,
Brazil, Mexico and the US. No escalated carbapenem resistance was
detected, but resistance to newer cephalosporins, aminoglycosides, cipro-
f1oxacin, and piperacillin/tazobactam was shown to have increased in most
geographic areas sampled. Meropenem was generally more active than
imipenem against Gram-negative bacilli but slightly less active against
Gram-positive cocci, e.g. Enterococcus faecalis (MIC90, 16-32 ILg/mL).
Pseudomonas aeruginosa isolates from the cystic fibrosis centres were pre-
dictably less susceptible to meropenem than those from intensive care unit,
hospital or neutropenic centres (MIC90, 32 vs. 4-8 ILg/mL); however
meropenem remained somewhat more potent than imipenem.
Conclusions: Results from the MYSTIC study indicate the continued in
vitro potency ofmeropenem against pathogens isolated in Europe, Latin and
North America. Emergence ofcarbapenem-resistant strains remains at a low
and stable level indicating that carbapenems continue to be a reliable option
for serious clinical infections. This is in contrast to other antibiotics tested
where some high level resistance was seen.
ITuI9-2! Gram-negative resistance: What do we do?
D. L. Paterson
Instituto lWediterraneo per i Trapianti e Terapie ad Alta Specializzazione
(ISMETT), Palermo, Italy
In contrast to the attention paid to Gram-positive resistance, recent increases
in the resistance of Gram-negative bacilli to antibiotics have not been
matched by the development of new antibiotics. Resistant isolates of
Klebsiella species producing extended-spectrum beta-lactamases (ESBLs)
were detected within months of the commercial release of the third-
generation cephalosporins. Apart from rare case reports. in vitro studies
show 100% susceptibility of these isolates to the carbapenems, with
meropenem consistently more active than imipenem. In contrast, approxi-
mately 20% of these ESBL-producing isolates are resistant to quinolones or
cefepime and resisunce to beta-Iactamfbeta-Iacumase inhibitor combina-
tions is seen even more frequendy. Clinical findings mirror these results,
with the carbapenems being consistently associated with positive clinical
outcome for serious infections. Carbapenems are also stable to chtomoso-
mally-mediated beta-lactamases produced by isolates such as Enterobacter
cloacae, and are a first-line treatment for serious infections caused by these
organisms. Quinolones and aminoglycosides are other options. Third-
generation cephalosporins should not be used to treat these organisms or
ESBL-producing isolates, regardless of their apparent in vitro susceptibility.
Acinetobacter species. Pseudomonas aeruginosa and Stenotrophomf»las maltophiUa
are other Gram-negative organisms that are increasingly being encountered
with resistance to multiple antibiotics. Unfortunately, we have entered the
new millennium with pessimism regarding our ability to treat multiply-
resistant Gram-negative isolates. At present, we must optimise our use of
existing effective compounds (e.g. the carbapenems) for first-line therapy in
patients with difficult-to-treat infections. and utilise strategies to prevent the
spread of resistant organisms within our hospitals.
ITu19-3 IVentilator-associated pneumonia: Dealing with
resistance
J. Garau
Hospital Mutua de Terrassa, Barcelona, Spain
Ventilator-associated pneumonia (VAP) is a prevalent condition frequently
caused by Gram-negative bacteria. VAP is associated with high morbidity
and mortality and prolonged hospitalisation, and therefore requires prompt
and effective first-line treatment. Increasing resistance in Gram-negative
organisms to commonly prescribed antibiotics means that choosing the right
first-line antimicrobial therapy for VAP is becoming more difficult. In a
recent study, resistance to the prescribed third-generation cephalosporin
(ceftazidime or ceftriaxone) was the most common reason for changing the
initial regimen in patients with VAP. Carbapenems have a broad spectrum
of antimicrobial activity and are active against bacteria resistant to other
beta-lactam antibiotics, including cephalosporins. In a recent prospective,
randomised study specifically focussed on YAP (the Spanish Collaborative
Group for the Study ofSevere Infections), meropenem (1 g iv every 8 h) was
more effective clinically (49/59 [83%)) than ceftazidime plus amikacin (39/59
[66%); P = 0.035). The most common causative pathogens in this study
were Gram-negative aerobes (Pseudomonas aeruginosa, Haemophilus injluen-
zae and enteric bacteria being the most prevalent). Thus, as there are few
antimicrobial agents either currently available or in clinical development
that can combat life-threatening multiply-resistant Gram-negative patho-
gens, the carbapenems, for example meropenem, should be considered as a
first-line empirical therapy for this indication.
ITuI9-41 Gram-positive resistance: What do we do?
R. C. Moellering
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Antimicrobial resistance is a serious threat to the clinical effectiveness of
antibiotics, particularly for infections caused by Gram-positive cocci.
Selective pressure from extensive antimicrobial use is the major factor
leading to resistance. Whilst the implementation of infection control
techniques and the appropriate use of available agents are vital, they are
failing to stem the tide of antimicrobial resistance. Several new approaches
are being taken to develop novel agents with activity against multi-resistant
Gram-positive bacteria. One approach is the re-examination of agents
previously limited by administration difficulties or toxicity. For example,
the streptogramin combination, quinupristin/dalfopristin, has been recently
introduced only as an intravenous formulation suitable for treating seriously
ill patients. Alternative methods of administration of daptomycin and
ramoplanin may overcome limitations due to toxicity. The favourable
activity of everninomicin has been known for several decades and a new
parenteral formulation is now being tested. The oxazolidinones represent a
completely new class of agent which inhibit protein synthesis by a novel
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mode of action and have activity against methicillin-resistant Slaphylococcus
aureus, penicillin-resistant pneumococci and vancomycin-resistant entero-
cocci. Other novel antibiotics arc being developed through chemical
modification ofexisting agents. such as the alteration of the ftuoroquinolone
nucleus or synthesis ofa glycopeptide related to vancomycin. Bacteriophage
therapy is being developed to treat multiply resistant E1Ilao(Occus faecium
infections. Furthermore, antisense constructs used alone or as adjuncts to
bacteriophage therapy maybe useful for reversing vancomycin resistance.
Thus. many approaches are being investigated to combat increasing levels of
multiresistant Gram-positive bacteria.
ITu19-sl Meningitis: Consequences of resistance on the choice
of treatment
K. P. Klugman
Pneumococcal Diseases Research Unit, Johanllesburg, South Africa
The empirical management ofbacterial meningitis has changed over the past
decade as a direct result of decreasing susceptibility to antimicrobials by the
major bacterial causes ofthis disease. Ampicillin and chloramphenicol can no
longer be considered for initial therapy; pneumococci are increasingly
resistant to penicillins worldwide, and chloramphenicol-resistance remains
common in developing countries. Resistance is rapidly spreading through
the dissemination of multi-resistant pneumococcal clones. Pneumococci
have also acquired resistance to the third-generation cephalosporins, cefo-
taxime and ceftriaxone. Where cephalosporin resistance is known to occur.
the addition of vancomycin should be considered. Strains of Neisseria
mellillgilidis resistant to chloramphenicol have emerged. as have strains
with intermediate penicillin-resistance. The incidence of chloramphenicol-
resistant strains of Hannophilus il!fiuenzae has increased in frequency in
Africa. and betalaetamase producing strains remain common worldwide.
Gram-negative bacteria and Listtria (isolated more rarely in meningitis) also
exhibit multiresistance to cephalosporins. Thus there is an urgent need for
more active drugs for the trearment of meningitis. The carbapenerns have
enhanced in vitro activity against bacterial pathogens compared with the
third-generation cephalosporins. Three randomised comparative trials have
compared meropenem with cefotaxime and/or ceftriaxone in bacterial
meningitis. Meropenem was as clinically efficacious and as well tolerated
as the cephalosporins in these studies. Furthermore, to date there have been
no bacteriologically documented failures of meropenem in cephalosporin-
resistant pneumococcal meningitis. Current empiric management ofmenin-
gitis is based on the use ofcefotaxime or ceftriaxone plus vancomycin. With
increasingly widespread resistance to existing antimicrobial agents, mono-
therapy with meropenem represents an alternative tre.atnl':nt regim.en.
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ITUI14-1I Control of hospital acquired bacterial resistance:
Implications for empiric therapy selection
M. J. Struelens. B. Byl, J. L. Vincent
Unive,site Libre de Bruxelles, Hopilal Erasme, Brussels, Belgium
Increasing antibiotic resistance ofbacterial pathogens is limiting the options
for empiric therapy of nosocomial infection. Resistance increases as a result
of selection of resistant mutants. acquisition of mobile resistance determi-
nants and epidemic spread ofmulti-resistant clones. The selection pressure of
antibiotic use contributes to all these mechanisms so that interventions aimed
at reducing or modulating this selective pressure through antibiotic policy
are currently evaluated. In a number of settings. both hospital-wide or in
intensive care or oncology department, restriction of prescription of
frequently used agents like third generation cephalosporins or ftuoroquino-
lones have been attempted to control resistance to these drugs ofnosocomial
Gram-negative rods. including Klebsiella spp. ElIlerobaCler spp and Acineto-
baCler spp. In several studies. this policy. with or without additional infection
control measures. appeared effective in reducing the incidence of coloniza-
tion or infection with multi-resistant strains. In our tertiary care center in a
country where multi-resistant ElIlerobaCler aerogenes has become endemic, we
performed an antibiotic policy intervention in the department of intensive
care to reduce the incidence ofMR-E. aerogenes colonization. Compared to a
6-month baseline. the use of third generation cephalosporins was reduced in
the 32-month intervention period by 82%. that offtuoroquinolones by 86%
and cefepime was added to the formulary for empiric therapy. We observed
a significant and persistent reduction in the resistance of Enrerobacleriaceae
(but not of Pseudomonas aeruginosa) to these drugs as well as • significant
reduction in the incidence rate of MR-E. aerogenes. These data illustrate the
usefulness ofadapting empiric policy regimens in high-risk hospital units to
improve the local ecology ofresistance. A rotation strategy may represent a
worthwhile option.
[ThI14-2ICefepime for multiple antibiotic resistant GNR
infections
M.Joshi l • R. Brul11• N. Sompalil • S. Qaiyurni.J. A.Johnson
IRA Cowley Shock Trauma Cmler, Ballimore, USA
Third-generation cephalosporins (3C) were considered first-line antibiotics
for treating serious gram-negative rod (GNR) infections. Recently. expres-
sion of AmpC cephalosporinase (AmpC) and extended spectrum ~lacta­
rna.., (ESBL) in GNR has resulted in widespread resistance to 3C. Cefepime.
the new cephalosporin. requires two distinct mutational events for devel-
opment of resistance. thereby decreasing the likelihood of resistance.
Although in vitro data demonstrates the enhanced activity of cefepime
against these strains. clinical data is bcking.
Methods: In an 18-month retrospective study. we identified 14 patients
treated with cefepime for resistant GNR infections. CDC guidelines were
used to identify infection. GNR included in the study had diminished zones
of inhibition around 3C. aztreonam. and cefpodoxime disks. Ten of the 14
p.thogens were screened for ESBl production by NCClS guidelines.
Clavulate-resistant strains may carry AmpC.
Results: The mean length ofstay was 45.4 days. prior antibiotics were used
in 12 patients. the mean age of the patients was 52.4 years of age. the male:
female ratio was 8:6. and the mean day of GNR acquisition was 26.4. The
infection sites included pulmonary (4 p), skin and soft tissue (5 p). and CSF/
Bone/BloodJIAA/Urine (5 pl.
No. ESBl/
Pathogens patient' AmpC Outcomes Clinical Bacterial
K pneumoniae 5 3/1 Cure 11 13
K oxytoca 2 I/O failure 1 0
Not evalu-
E coli 2 2/0 able 2
E cloacae 5 0/3
Condusions: Cefepime was effective in a small number ofpatients. Larger
studies arc needed to confirm these results.
!TuI14-3I Empiric therapy of nosocomial pneumonia in
intensive care unit patients
G. Zanetti
Ha"'ard University, Boslon, Uniled S,a'es
Early appropriate antibiotic therapy diminishes mortality in intensive care
unit (ICU) patients with nosocomial pneumonia. However. the poor
specificity ofclinical and microbiological diagnosis ofnosocomial pneumo-
nia and the wide array of possible pathogens make the empiric choice of
antibiotics difficult. Monotherapy with broad-spectrum antibiotics recently
emerged as an appealing option.
Objective: To compare the efficacy of cefepime. 2 g three times a day. and
imipenem/cilastatin. 0.5 g four times a day. as monotherapy for ICU patients
with nosocomial pneumonia.
Methods: The randomized. open-label. evaluator-blind study was con-
ducted in 13 centers from six European countries. Sixty-six percent of the
270 eligible patients had mechanical ventilation. The mean APACHE II
score was 16 at randomization.
Results: Microbiological documentation was available for 180 patients
(67%). The most frequent causative organism was Pseudomonas aeruginosa,
which occurred in 70 patients. In each group. 86% ofthe causative organisms
were susceptible to the allocated regimen. Success rate (cure or improve-
ment) in intent-to-treat analysis was similar with cefepime (59%) and
imipenem/cilastatin (57%). Clinical failure was attributed to resistance of
the causative organism in 5.3% of the cefepime patients and 5.8% of the
imipenem/cilastatin patients. Among microbiologically documented noso-
comial pneumonia. eradication rates were 52% with cefepime and 44% with
imipenem/cilastatin. Resistance to the allocated regimen occurred in 4.1 %
of the causative organisms in cefepime and 6.9% ofthe causative organisms
in imipenem/cilastatin. Nosocomial pneumonia contributed to the death of
11 patients in cefepime .nd eight patients in imipenem/cilastatin.
